Japanese Drug Maker's Blood Thinner Appears Safer Than Standard Treatment
AMSTERDAM—Results from a highly anticipated study of Japanese drug maker Daiichi Sankyo Co.'s experimental medication to reduce blood clots showed that it appeared to work as well as the current standard treatment—though no better—and is safer.
Read more on Wall Street Journal

Gene Breakthroughs Spark a Revolution in Cancer Treatment
The newfound variants have led major cancer centers to revamp their approach to treating cancer and have spurred a rush among drug companies to find medicines that narrowly target each one. The drugs don't cure cancer and face significant hurdles.
Read more on Wall Street Journal

New Diabetes Drugs Don't Raise Heart-Attack Risk
Patients with Type 2 diabetes and a history of, or at risk for, cardiovascular events were randomly given the medicine or a placebo as well as other standard treatment and were followed for two years on average. The other study, called Examine, was a …
Read more on Wall Street Journal